Table 2.
Base-case effectiveness and safety of 15 treatment sequences according to median OS.
| Treatment Sequence | Median OS (mo) | NNT | 36-Month OS (%) | LYG (yr) | SAEs (%) |
|---|---|---|---|---|---|
| Lenvatinib-Nivolumab | 27 | 5 | 32.9 | 0.75 | 48.0 |
| Lenvatinib-Pembrolizumab | 25 | 7 | 26.8 | 0.58 | 64.4 |
| Atezolizumab plus Bevacizumab-Nivolumab | 24 | 6 | 29.5 | 0.50 | 40.2 |
| Sorafenib-Nivolumab | 23 | 7 | 26.1 | 0.42 | 46.3 |
| Atezolizumab plus Bevacizumab-Pembrolizumab | 23 | 9 | 23.4 | 0.42 | 57.1 |
| Lenvatinib-Ramucirumab | 22 | 13 | 19.9 | 0.33 | 72.8 |
| Lenvatinib-Regorafenib | 22 | 14 | 19.3 | 0.33 | 77.2 |
| Lenvatinib-Cabozantinib | 22 | 14 | 19.2 | 0.33 | 77.2 |
| Sorafenib-Pembrolizumab | 20 | 15 | 18.9 | 0.17 | 62.9 |
| Atezolizumab plus Bevacizumab-Ramucirumab | 20 | 23 | 16.7 | 0.17 | 65.6 |
| Atezolizumab plus Bevacizumab-Regorafenib | 20 | 29 | 15.8 | 0.17 | 70.0 |
| Atezolizumab plus Bevacizumab-Cabozantinib | 20 | 30 | 15.6 | 0.17 | 69.9 |
| Sorafenib-Cabozantinib | 18 | 83 | 11.1 | 0.00 | 75.8 |
| Sorafenib-Regorafenib | 18 | 200 | 11.8 | 0.00 | 75.9 |
| Sorafenib-Ramucirumab | 18 | - | 12.3 | 0.00 | 71.4 |
LYG, life-year gained. All the sequences were compared to the worst sequence (Sorafenib-Ramucirumab). OS, overall survival. SAEs, severe adverse events. NNT, number needed to treat. yr, years. mo, months.